Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial

European Respiratory Journal

Volumn 42, Issue 6, 2013, Pages 1622-1632

  Raghu, Ganesh ^a   Million Rousseau, Rachel ^b   Morganti, Adele ^b   Perchenet, Loïc ^b   Behr, Juergen ^c   Goh, N ^d   Glanville, A ^e   Musk, M ^f   Hopkins, P ^g   Lien, D C ^h   Chan, C ⁱ   Rolf, J D ^j   Wilcox, P ^k   Cox, P G ^l   Manganas, H ^m   Cottin, V ⁿ   Valeyre, D ^o   Walleart, B ⁿ   Andreas, S ^p   Neurohr, C ^q   Guenther, A ^r   Schonfeld N ^s   Koch, A ^t   Kramer, M ^u   Breuer, R ^v   Ben Dov, I ^w   Fink, G ^x   Schwarz, Y ^y   Albera, C ^z   Confalonieri, M ^aa   Saltini, C ^ab   Harari, S ^ac   Flezar, M ^ad   Greenblatt, M ^ae   Ras, G J ^ae   Morell, F ^af   Alvarez Sala, J L ^ag   Xaubet, A ^ah   Sueiro, A ^ai   Linares, M J ^aj   Skold M ^ak   Kayacan, O ^al   Mogulkoc, N ^am   Chan, A ^an   Chapman, J ^ao   Parambil, J ^ao   Ettinger, N ^ap   Golden, J ^aq   Meyer, K C ^ar   Swigris, J J ^as   Yung, G L ^at   Antin Ozerkis, D ^au   Mohabir, P K ^av   Wesselius, L J ^aw   De Andrade, J ^ax   Cordova, F ^ay   Safdar, Z ^az   Wencel, M ^ba   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d ALFRED HOSPITAL   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g Thoracic Department   (Australia)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j KELOWNA GENERAL HOSPITAL   (Canada)

^k ST PAUL S HOSPITAL   (Canada)

^l MCMASTER UNIVERSITY   (Canada)

^m NOTRE DAME HOSPITAL   (Canada)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o AVICENNE HOSPITAL   (France)

^p Fachklinik fur Lungenerkrankungen   (Germany)

^q LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^r JUSTUS LIEBIG UNIVERSITY   (Germany)

^s HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^t UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^u RABIN MEDICAL CENTER   (Israel)

^v HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^w SHEBA MEDICAL CENTER   (Israel)

^x KAPLAN MEDICAL CENTER   (Israel)

^y TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^z Azienda Ospedaliera   (Italy)

^aa UNIVERSITY OF TRIESTE   (Italy)

^ab TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^ac San Giuseppe Hospital   (Italy)

^ad UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^ae MILPARK HOSPITAL   (South Africa)

^af Hospital Univeristari Vall D'Hebrón   (Spain)

^ag HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^ah HOSPITAL CLÍNIC   (Spain)

^ai HOSPITAL RAMÓN Y CAJAL   (Spain)

^aj HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^ak KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^al ANKARA UNIVERSITY   (Turkey)

^am EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^an UNIVERSITY OF CALIFORNIA   (United States)

^ao LERNER RESEARCH INSTITUTE   (United States)

^ap Cardio Pulmonary Associates   (United States)

^aq UNIVERSITY OF CALIFORNIA   (United States)

^ar University of Wisconsin Health   (United States)

^as DEPARTMENT OF MEDICINE   (United States)

^at UNIVERSITY OF CALIFORNIA   (United States)

^au YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^av STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^aw MAYO CLINIC   (United States)

^ax UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^ay TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^az BAYLOR COLLEGE OF MEDICINE   (United States)

^ba Wichita Clinic   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; MACITENTAN; PLACEBO; PREDNISONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHITIS; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY TRACT PARAMETERS; SURVIVAL RATE; TRANSITION DYSPNOEA INDEX; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84888166435     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00104612     Document Type: Article

References (31)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355-361.
3. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
4. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
5. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
6. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
7. Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 44: 1-10.
8. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
9. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
10. Raghu G, Behr J, Brown KK, et al. ARTEMIS-IPF: A placebo-controlled trial of ambrisentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: A3632.
11. Iglarz M, Landskroner K, Rey M, et al. Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 183: A6445.
12. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
13. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
14. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
15. Raghu G, King TE Jr, Behr J, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35: 118-123.
16. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
17. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
18. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.
19. Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2012; 43: 2671-2676.
20. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012; 30: 93-99.
21. Epstein BJ. Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Ann Pharmacother 2008; 42: 1060-1069.
22. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
23. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
24. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
25. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
26. Taniguchi H, Kondoh Y, Ebina M, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011; 12: 93.
27. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
28. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
29. Behr J, Demedts M, Buhl R, et al. Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Respir Res 2009; 10: 101.
30. Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011; 377: 1727-1729.
31. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-1048.